(Q38076757)

28 August 2017

1 reference

title

Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C. (English)

1 reference

28 August 2017

1 reference

Carolina Scagnolari

1

1 reference

28 August 2017

Guido Antonelli

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

28 January 2013

1 reference

Expert Opinion on Biological Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

693-711

1 reference

Virus interference. I. The interferon

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Pattern recognition receptors and the innate immune response to viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Interferon-inducible antiviral effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Interferons and microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

An overview of HCV molecular biology, replication and immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Production of type I interferons: plasmacytoid dendritic cells and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

A species of human alpha interferon that lacks the ability to boost human natural killer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Different antiviral activities of IFN-alpha subtypes in human liver cell lines: synergism between IFN-alpha2 and IFN-alpha8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Enhanced anti-HCV activity of interferon alpha 17 subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

In vitro sensitivity of human metapneumovirus to type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Interleukin-29 suppresses hepatitis A and C viral internal ribosomal entry site-mediated translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

The IFN gamma receptor: a paradigm for cytokine receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Interferon-γ: an overview of signals, mechanisms and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Differential receptor subunit affinities of type I interferons govern differential signal activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Intracellular DNA recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

INTERFEROME: the database of interferon regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

The ISG56/IFIT1 gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

ISG15, not just another ubiquitin-like protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

The cell biology of TRIM5α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Tetherin and its viral antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

The small interferon-induced transmembrane genes and proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Viperin: a multifunctional, interferon-inducible protein that regulates virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Hepatitis C virus NS3/4A protease blocks IL-28 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKKε and TBK1 functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Expert opinion on the treatment of patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Current progress in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Is interferon-beta an alternative treatment for chronic hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

An orally available, small-molecule interferon inhibits viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Interferon signaling and treatment outcome in chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

MxA and PKR expression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Antibodies Neutralizing Peginterferon Alfa during Retreatment of Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

Expression of biomarkers of interferon type I in patients suffering from chronic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.764409

10.1517/14712598.2013.764409

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference